Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.

@article{Haddad2009RandomizedP2,
  title={Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer.},
  author={Robert I. Haddad and Stephen T. Sonis and Marshall Roy Posner and Lori J Wirth and Rosemary Costello and Patricia Braschayko and Aaron M Allen and Anand Mahadevan and Jayme Flynn and Elaine Burke and Yi Li and Roy B. Tishler},
  journal={Cancer},
  year={2009},
  volume={115 19},
  pages={4514-23}
}
BACKGROUND A randomized phase 2 study was performed to investigate the efficacy/toxicity of combining concomitant boost radiation and weekly carboplatin/paclitaxel with or without amifostine in patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN). METHODS Patients with newly diagnosed, locally advanced stage III or IV SCCHN received 4 weekly doses of carboplatin (area under the curve, 1.5) and paclitaxel (45 mg/m(2)) concurrently with concomitant boost radiation… CONTINUE READING
28 Extracted Citations
19 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 28 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 19 references

A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemother apy for locally advanced oropharyngeal carcinoma

  • NY Lee, FF de Arruda, DR Puri
  • Int J Radiat Oncol Biol Phys. 2006;66:966-974
  • 2006
1 Excerpt

Similar Papers

Loading similar papers…